Results 91 to 100 of about 1,325,573 (304)
Therapeutic Monoclonal Antibodies
The Keio Journal of Medicine, 2011 Over a hundred years has passed since the discovery of the "magic bullet" serum therapy by Kitasato and Behring, the first ever therapeutic use of antibodies. More than 80 years later, the investigation of immunoglobulin structure and function and the development of cell and molecular biology introduced the production of monoclonal antibodies (MoAbs ...
openaire +3 more sources
Molecular Oncology, EarlyView.LVRF (lymphatic and vascular resistance factor) is a VEGFA splice variant upregulated in response to anti‐angiogenic therapy that fosters tumor adaptation through enhanced vascularization, lymphangiogenesis, and metastatic dissemination. Targeting LVRF with fully human neutralizing antibodies disrupts these processes and limits resistant tumor growth ...
Marion David +12 more
wiley +1 more source
Human monoclonal antibodies that neutralize anthrax toxin by inhibiting heptamer assembly [PDF]
, 2004 A panel of human anti-anthrax protective antigen IgG1 monoclonal antibodies were evaluated to determine the mechanism of toxin neutralization. AVP-22G12, AVP-1C6 and AVP-21D9 bound to the protective antigen with picomolar affinities to distinct non ...
Jiang, I. +7 more
core
USP7 inhibits FOXO1 activity in chronic lymphocytic leukaemia cells enhancing cell survival
Molecular Oncology, EarlyView.CLL cells rely on BCR‐mediated signalling for survival and proliferation in part through suppression of FOXO1. FOXO1 activity is regulated by a plethora of post‐translational modifications including phosphorylation and ubiquitination. We demonstrated that dual inhibition of BCR signalling and the deubiquitinase USP7 activates FOXO1, modulating its ...
Hassan N.B. Almuhanna +8 more
wiley +1 more source
ImmunobiologyMonoclonal antibodies are playing an increasingly important role in modern medicine. Human monoclonal antibodies have become a key focus in the development of monoclonal antibody therapeutics due to their safety.
Guanglei Gu +6 more
doaj +1 more source
Systemic characteristic of safety profile of monoclonal antibodies used in rheumatology practice
Качественная клиническая практика, 2019 Monoclonal antibodies are highly effective medications, which made a breakthrough in medicine. Taking into consideration the properties of monoclonal antibodies safety plays a key role in “risk-benefit” assessment.
A. V. Philippova +4 more
doaj +1 more source
Loss of AMBRA1 activates MAPK and angiogenesis signaling pathways in melanoma cells
FEBS Open Bio, EarlyView.Loss of AMBRA1 in melanoma cells activates multiple oncogenic pathways associated with tumor progression. Transcriptomic and protein network analyses revealed that AMBRA1 depletion enhances MAPK/ERK signaling, angiogenesis, TGF‐β/EMT signaling, and Wnt/axon guidance pathways.
Milad Ibrahim +4 more
wiley +1 more source
An investigation of the molecular basis of interactions between human monoclonal antibodies and antigens that are clinically relevant in systemic lupus erythematosus and the Antiphospholipid Syndrome. [PDF]
, 2007 Autontibodies to a wide variety of antigens are associated with systemic lupus erythematosus (SLE) and the Antiphospholipid Syndrome (APS).
Lambrianides, A.
core
Monoclonal antibodies for diagnosis of enterovirus 71
, 2014 [[abstract]]Enterovirus 71 (EV71), one of the major causative agents of hand, foot, and mouth disease (HFMD), is now recognized as an emerging neurotropic virus in Asia and may cause severe neurologic complications and mortalities.
Xu, L;Huang, KJ;Ho, TS;Liu, CC;Lee, YR;Lin, CY;Shiuan, D;Jiang, XH
core +1 more source
Treatment patterns and factors associated with discontinuation of monoclonal antibodies
SAGE Open MedicineBackground: Biological agents have revolutionized care in specialties such as oncology, immunology, infectious diseases, and genetic disorders, offering targeted actions on specific molecules or select immune cells. Monoclonal antibodies, known for their
Muzoon Matar Saleh Alkaabi +3 more
doaj +1 more source